July 6, 2020 / 11:31 AM / a month ago

BRIEF-Esperare Receives FDA Breakthrough Therapy Designation For Investigational Prenatal Treatment ER-004 In X-Linked Hypohidrotic Ectodermal Dysplasia

July 6 (Reuters) -

* ESPERARE RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR INVESTIGATIONAL PRENATAL TREATMENT ER-004 IN X-LINKED HYPOHIDROTIC ECTODERMAL DYSPLASIA (XLHED) Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below